New pill hopes to tame rare blood cancer in japanese patients
NCT ID NCT07387471
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a cancer pill called venetoclax in 14 Japanese adults with a rare blood cancer (Waldenström macroglobulinemia) that has come back or not responded to treatment. Participants take the drug by mouth daily, with doses slowly increased. The main goal is to see how many patients have a major reduction in their cancer. The study lasts about 28 months and involves regular check-ups and blood tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax (a targeted cancer pill)
What this could lead to
If successful, this could offer a new oral treatment option for Japanese patients with Waldenström macroglobulinemia that has stopped responding to prior therapy.
What could go wrong
This is a small, early-phase study (14 people) with no placebo comparison. The drug may not work as hoped, and side effects like low blood counts or infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOPLASMACYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chiba Cancer Center /ID# 279177
RECRUITINGChiba, 260-0801, Japan
-
Gunma University Hospital /ID# 277576
RECRUITINGMaebashi, Gunma, 371-8511, Japan
-
Hiroshima University Hospital /ID# 279172
RECRUITINGHiroshima, Hiroshima, 734-8551, Japan
-
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 279178
RECRUITINGNagoya, Aichi-ken, 466-8650, Japan
-
Japanese Red Cross Medical Center /ID# 277577
RECRUITINGShibuya-ku, Tokyo, 150-8935, Japan
-
Kindai University Hospital /ID# 277587
RECRUITINGSakai-shi, Osaka, 590-0197, Japan
-
Kyushu University Hospital /ID# 277582
RECRUITINGFukuoka, Fukuoka, 812-8582, Japan
-
NHO Mito Medical Center /ID# 279175
RECRUITINGHigashiibaraki-gun, Ibaraki, 311-3193, Japan
-
Nagano Red Cross Hospital /ID# 279774
RECRUITINGNagano, 380-8582, Japan
-
Nagoya City University Hospital /ID# 277580
RECRUITINGNagoya, Aichi-ken, 467-8602, Japan
-
National Cancer Center Hospital /ID# 279076
RECRUITINGChuo-Ku, Tokyo, 104-0045, Japan
-
National Hospital Organization Disaster Medical Center /ID# 277741
RECRUITINGTachikawa, Tokyo, 190-0014, Japan
-
The Cancer Institute Hospital Of JFCR /ID# 277579
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
-
The University of Tokyo Hospital /ID# 279174
RECRUITINGBunkyo-ku, Tokyo, 113-8654, Japan
-
University Hospital Kyoto Prefectural University of Medicine /ID# 277584
RECRUITINGKyoto, Kyoto, 602-8566, Japan
-
University of Fukui Hospital /ID# 279173
RECRUITINGYoshida-gun, Fukui, 910-1104, Japan
-
University of Yamanashi Hospital /ID# 279179
RECRUITINGChuo-shi, Yamanashi, 409-3898, Japan